CTNM – contineum therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Robert W. Baird from $16.00 to $14.00. They now have an "outperform" rating on the stock.
Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Royal Bank Of Canada from $25.00 to $22.00. They now have an "outperform" rating on the stock.
Contineum falls after missing main goals in multiple sclerosis trial [Seeking Alpha]
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) [Yahoo! Finance]
Form 8-K Contineum Therapeutics, For: Nov 20
Form SCHEDULE 13G/A Contineum Therapeutics, Filed by: FRANKLIN RESOURCES INC
Form 10-Q Contineum Therapeutics, For: Sep 30
Form 8-K Contineum Therapeutics, For: Oct 30
Form 8-K Contineum Therapeutics, For: Sep 18
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.